ABVC BioPharma Inc

NASDAQ:ABVC  
0.89
+0.01 (+1.15%)
Products, Regulatory

ABVC Provides Oncology Pipeline Updates

Published: 08/22/2022 12:42 GMT
ABVC BioPharma Inc (ABVC) - Abvc Provides Oncology Pipeline Updates.
Abvc Biopharma Inc - Expects to Initiate First Phase Ii Clinical Trials for Abv-1703 in Q2 of 2023.
Abvc Biopharma Inc - Sees Studies for Abv-1519 for Non-small Cell Lung Cancer, Abv-1501 for Triple Negative Breast Cancer to Be Initiated in Q3 2023.
Abvc Biopharma Inc - Clinical Study for Abv-1702 for Myelodysplastic Syndrome is Expected to Start in Q4 of 2023.
Abvc Biopharma Inc - Plans to Submit Abv-1703's Phase Ii Clinical Trial Ind to Taiwan FDA After Commencing Clinical Trials in United States.